Get access

Glycyrrhizin versus antiviral drugs for chronic hepatitis B virus infection

  • Protocol
  • Intervention

Authors

  • Yun Xia,

    Corresponding author
    1. b) Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, a) Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, Beijing, China
    • Yun Xia, a) Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, b) Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. xiayun_xy@126.com.

    Search for more papers by this author
  • Jian Ping Liu,

    1. b) National Research Centre in Complementary and Alternative Medicine (NAFKAM), Tromsø, Norway, c) Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Copenhagen, Denmark, a) Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China, Beijing, China
    Search for more papers by this author
  • Christian Gluud

    1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the benefits and harms of glycyrrhizin preparations for patients with chronic HBV infection.